- Home
- CNMD vs CNTA Comparison
CNMD vs CNTA Comparison
Compare CNMD & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNMD | CNTA |
|---|---|---|
| Founded | 1970 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 3.5B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNMD | CNTA |
|---|---|---|
| Price | $35.95 | $26.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $48.00 | $40.89 |
| AVG Volume (30 Days) | 381.5K | ★ 1.1M |
| Earning Date | 04-29-2026 | 03-27-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $1,374,724,000.00 | N/A |
| Revenue This Year | $0.82 | N/A |
| Revenue Next Year | $5.48 | N/A |
| P/E Ratio | $24.37 | ★ N/A |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $35.37 | $9.60 |
| 52 Week High | $61.25 | $30.58 |
Technical Indicators
Market Signals| Indicator | CNMD | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 26.64 | 51.06 |
| Support Level | $35.37 | $24.62 |
| Resistance Level | $46.08 | $27.56 |
| Average True Range (ATR) | 1.42 | 1.37 |
| MACD | -0.56 | 0.02 |
| Stochastic Oscillator | 2.77 | 43.26 |
Price Performance
Historical ComparisonAbout CNMD CONMED Corporation
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.